ARMP
Armata Pharmaceuticals, Inc.
Biotechnology
Market Cap$331M
5Y Perf.+109.1%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
ARMP vs PHGE vs LSTA vs ACXP vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PHGE
BiomX Inc.
Biotechnology
Market Cap$1.01B
5Y Perf.-99.9%
LSTA
Lisata Therapeutics, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-87.0%
ACXP
Acurx Pharmaceuticals, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-98.4%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.+20.4%
ARMP vs PHGE vs LSTA vs ACXP vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ARMP | PHGE | LSTA | ACXP | PRAX |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $331M | $1.01B | $29M | $5M | $9.63B |
| Revenue (TTM) | $5M | $0.00 | $170K | $0.00 | $-92K |
| Net Income (TTM) | $-47M | $-36M | $-17M | $-7.97B | $-327M |
| Gross Margin | 70.5% | — | 91.2% | — | — |
| Operating Margin | -6.6% | — | -107.1% | — | — |
| Total Debt | $127M | $1M | $0.00 | $0.00 | $110K |
| Cash & Equiv. | $9M | $5M | $16M | $7.56B | $357M |
ARMP vs PHGE vs LSTA vs ACXP vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ARMP
PHGE
LSTA
ACXP
PRAX
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | 100 | 209.1 | +109.1% |
| BiomX Inc. (PHGE) | 100 | 0.1 | -99.9% |
| Lisata Therapeutics… (LSTA) | 100 | 13.0 | -87.0% |
| Acurx Pharmaceutica… (ACXP) | 100 | 1.6 | -98.4% |
| Praxis Precision Me… (PRAX) | 100 | 120.4 | +20.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARMP vs PHGE vs LSTA vs ACXP vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRAX leads in 3 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Armata Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. PHGE also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ARMP
Armata Pharmaceuticals, Inc.
The Growth Play
ARMP is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 14.2%, EPS growth 72.6%, 3Y rev CAGR 5.0%
- 14.2% revenue growth vs PRAX's -100.0%
Best for: growth exposure
PHGE
BiomX Inc.
The Defensive Pick
PHGE ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 1.14, current ratio 0.87x
- Beta 1.14 vs ACXP's 2.42
Best for: sleep-well-at-night
LSTA
Lisata Therapeutics, Inc.
The Income Pick
LSTA is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 1 yrs, beta 1.17
- Beta 1.17, current ratio 5.76x
Best for: income & stability and defensive
ACXP
Acurx Pharmaceuticals, Inc.
The Healthcare Pick
Among these 5 stocks, ACXP doesn't own a clear edge in any measured category.
Best for: healthcare exposure
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder
PRAX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -20.1% 10Y total return vs ARMP's -97.4%
- 2.4% margin vs LSTA's -97.6%
- +7.7% vs PHGE's -94.3%
- -40.2% ROA vs ACXP's -413.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARMP | 14.2% revenue growth vs PRAX's -100.0% |
| Quality / Margins | PRAX | 2.4% margin vs LSTA's -97.6% |
| Stability / Safety | PHGE | Beta 1.14 vs ACXP's 2.42 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs PHGE's -94.3% |
| Efficiency (ROA) | PRAX | -40.2% ROA vs ACXP's -413.5% |
ARMP vs PHGE vs LSTA vs ACXP vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2024
ARMP vs PHGE vs LSTA vs ACXP vs PRAX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGACXP
Who Leads Where
PRAX leads in 2 of 6 categories
ARMP leads 1 • LSTA leads 1 • PHGE leads 0 • ACXP leads 0 • 2 tied
Explore the data ↓ACXPAcurx Pharmaceuticals…
0leads
PHGEBiomX Inc.
0leads
LSTALisata Therapeutics, …
1leads
ARMPArmata Pharmaceutical…
1leads
PRAXPraxis Precision Medi…
2leads
6 Total Categories
CATEGORYLEADERvs ARMPvs LSTAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARMP4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX4/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
LSTA1/1
Income & Cash Flow (Last 12 Months)
ARMP leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARMP and PRAX operate at a comparable scale, with $5M and -$92,000 in trailing revenue. ARMP is the more profitable business, keeping -9.3% of every revenue dollar as net income compared to LSTA's -97.6%. On growth, ARMP holds the edge at -61.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARMPArmata Pharmaceut… | PHGEBiomX Inc. | LSTALisata Therapeuti… | ACXPAcurx Pharmaceuti… | PRAXPraxis Precision … |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5M | $0 | $170,000 | $0 | -$92,000 |
| EBITDAEarnings before interest/tax | -$32M | -$28M | -$18M | $35,910 | -$357M |
| Net IncomeAfter-tax profit | -$47M | -$36M | -$17M | -$8.0B | -$327M |
| Free Cash FlowCash after capex | -$27M | -$26M | -$16M | $4.6B | -$283M |
| Gross MarginGross profit ÷ Revenue | +70.5% | — | +91.2% | — | — |
| Operating MarginEBIT ÷ Revenue | -6.6% | — | -107.1% | — | — |
| Net MarginNet income ÷ Revenue | -9.3% | — | -97.6% | — | — |
| FCF MarginFCF ÷ Revenue | -5.4% | — | -94.1% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -61.0% | — | -90.0% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.9% | +17.1% | +40.0% | +98.2% | +2.7% |
ARMP leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ARMP and ACXP and PRAX each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ARMPArmata Pharmaceut… | PHGEBiomX Inc. | LSTALisata Therapeuti… | ACXPAcurx Pharmaceuti… | PRAXPraxis Precision … |
|---|---|---|---|---|---|
| Market CapShares × price | $331M | $1.0B | $29M | $5M | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $449M | $1.0B | $13M | -$7.6B | $9.3B |
| Trailing P/EPrice ÷ TTM EPS | -17.49x | -0.03x | -1.69x | -0.40x | -24.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 64.06x | — | 173.02x | — | — |
| Price / BookPrice ÷ Book value/share | — | — | 1.92x | 0.00x | 8.54x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — ARMP and ACXP and PRAX each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-6 for ACXP. On the Piotroski fundamental quality scale (0–9), ACXP scores 3/9 vs LSTA's 1/9, reflecting mixed financial health.
| Metric | ARMPArmata Pharmaceut… | PHGEBiomX Inc. | LSTALisata Therapeuti… | ACXPAcurx Pharmaceuti… | PRAXPraxis Precision … |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -2.7% | -85.5% | -6.0% | -43.0% |
| ROA (TTM)Return on assets | -54.5% | -80.4% | -70.8% | -4.1% | -40.2% |
| ROICReturn on invested capital | -44.2% | -4.4% | -2.3% | — | -65.0% |
| ROCEReturn on capital employed | -70.7% | -66.6% | -82.7% | — | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 | 1 | 3 | 3 |
| Debt / EquityFinancial leverage | — | — | — | — | 0.00x |
| Net DebtTotal debt minus cash | $117M | -$4M | -$16M | -$7.6B | -$357M |
| Cash & Equiv.Liquid assets | $9M | $5M | $16M | $7.6B | $357M |
| Total DebtShort + long-term debt | $127M | $1M | $0 | $0 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -2.12x | -33.64x | — | — | — |
PRAX leads this category, winning 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARMP five years ago would be worth $21,942 today (with dividends reinvested), compared to $5 for PHGE. Over the past 12 months, PRAX leads with a +775.0% total return vs PHGE's -94.3%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs PHGE's -77.4% — a key indicator of consistent wealth creation.
| Metric | ARMPArmata Pharmaceut… | PHGEBiomX Inc. | LSTALisata Therapeuti… | ACXPAcurx Pharmaceuti… | PRAXPraxis Precision … |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +39.5% | -71.1% | +64.8% | -23.2% | +16.4% |
| 1-Year ReturnPast 12 months | +567.9% | -94.3% | +40.4% | -70.1% | +775.0% |
| 3-Year ReturnCumulative with dividends | +582.8% | -98.9% | -1.2% | -96.5% | +1976.5% |
| 5-Year ReturnCumulative with dividends | +119.4% | -99.9% | -85.8% | -98.7% | -20.8% |
| 10-Year ReturnCumulative with dividends | -97.4% | -100.0% | -96.8% | -98.7% | -20.1% |
| CAGR (3Y)Annualised 3-year return | +89.7% | -77.4% | -0.4% | -67.4% | +174.9% |
PRAX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PHGE and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
PHGE is the less volatile stock with a 1.14 beta — it tends to amplify market swings less than ACXP's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs PHGE's 4.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARMPArmata Pharmaceut… | PHGEBiomX Inc. | LSTALisata Therapeuti… | ACXPAcurx Pharmaceuti… | PRAXPraxis Precision … |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.05x | 1.09x | 2.31x | 1.40x |
| 52-Week HighHighest price in past year | $16.34 | $14.71 | $5.07 | $21.00 | $356.00 |
| 52-Week LowLowest price in past year | $1.17 | $0.61 | $1.81 | $1.33 | $35.18 |
| % of 52W HighCurrent price vs 52-week peak | +56.0% | +4.2% | +63.7% | +10.1% | +93.6% |
| RSI (14)Momentum oscillator 0–100 | 42.2 | 21.4 | 35.1 | 40.9 | 55.6 |
| Avg Volume (50D)Average daily shares traded | 50K | 193K | 76K | 3.6M | 378K |
Evenly matched — PHGE and PRAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
LSTA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ARMP as "Buy", PHGE as "Buy", PRAX as "Buy". Consensus price targets imply 6037.9% upside for PHGE (target: $38) vs 63.9% for ARMP (target: $15).
| Metric | ARMPArmata Pharmaceut… | PHGEBiomX Inc. | LSTALisata Therapeuti… | ACXPAcurx Pharmaceuti… | PRAXPraxis Precision … |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | — | — | Buy |
| Price TargetConsensus 12-month target | $15.00 | $38.00 | — | — | $548.80 |
| # AnalystsCovering analysts | 4 | 5 | — | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +100.0% | 0.0% |
LSTA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
PRAX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ARMP leads in 1 (Income & Cash Flow). 2 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 2 of 6 categories
Loading custom metrics...
ARMP vs PHGE vs LSTA vs ACXP vs PRAX: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ARMP or PHGE or LSTA or ACXP or PRAX a better buy right now?
For growth investors, Armata Pharmaceuticals, Inc.
(ARMP) is the stronger pick with 14. 2% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARMP or PHGE or LSTA or ACXP or PRAX?
Over the past 5 years, Armata Pharmaceuticals, Inc.
(ARMP) delivered a total return of +119. 4%, compared to -99. 9% for BiomX Inc. (PHGE). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus PHGE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARMP or PHGE or LSTA or ACXP or PRAX?
By beta (market sensitivity over 5 years), BiomX Inc.
(PHGE) is the lower-risk stock at 1. 05β versus Acurx Pharmaceuticals, Inc. 's 2. 31β — meaning ACXP is approximately 120% more volatile than PHGE relative to the S&P 500.
04Which is growing faster — ARMP or PHGE or LSTA or ACXP or PRAX?
By revenue growth (latest reported year), Armata Pharmaceuticals, Inc.
(ARMP) is pulling ahead at 14. 2% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Armata Pharmaceuticals, Inc. grew EPS 72. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ARMP or PHGE or LSTA or ACXP or PRAX?
BiomX Inc.
(PHGE) is the more profitable company, earning 0. 0% net margin versus -97. 6% for Lisata Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0. 0% versus -107. 1% for LSTA. At the gross margin level — before operating expenses — LSTA leads at 14. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ARMP or PHGE or LSTA or ACXP or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ARMP or PHGE or LSTA or ACXP or PRAX better for a retirement portfolio?
For long-horizon retirement investors, BiomX Inc.
(PHGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05)). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PHGE: -100. 0%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARMP and PHGE and LSTA and ACXP and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.